INTELLIGENT BIO SOLUTIONS INC.
For the period ended Jun 30, 2025. Filed Aug 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Aug 15, 2025
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED BALANCE SHEETS
| As of June 30, | As of June 30, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $1,019,909 | $6,304,098 |
| Accounts receivable, net | 594,614 | 429,704 |
| Inventories, net | 635,215 | 777,537 |
| Research and development tax incentive receivable | 734,408 | 525,332 |
| Assets held for sale | 327,500 | - |
| Other current assets | 826,976 | 497,572 |
| Total current assets | 4,138,622 | 8,534,243 |
| Property and equipment, net | 251,325 | 565,850 |
| Operating lease right-of-use assets | 69,520 | 306,744 |
| Intangibles, net | 3,790,319 | 4,372,026 |
| Total assets | $8,249,786 | $13,778,863 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $4,534,246 | $1,704,568 |
| Current portion of operating lease liabilities | 84,659 | 274,834 |
| Deferred grant income | - | 2,486,668 |
| Current employee benefit liabilities | 534,990 | 469,381 |
| Notes payable | 197,146 | 515,282 |
| Total current liabilities | 5,351,041 | 5,450,733 |
| Employee benefit liabilities, less current portion | 84,921 | 63,615 |
| Operating lease liabilities, less current portion | - | 81,324 |
| Total liabilities | 5,435,962 | 5,595,672 |
| Commitments and contingencies (Note 16) | - | - |
| Shareholders’ equity | ||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 7,323,377 and 7,323,261 shares issued and outstanding, as of June 30, 2025, respectively; 3,456,116 and 3,456,000 shares issued and outstanding, as of June 30, 2024 respectively | 73,230 | 34,557 |
| Treasury stock, at cost, 116 shares as of June 30, 2025 and 2024 | (1) | (1) |
| Additional paid-in capital | 65,783,916 | 60,971,740 |
| Accumulated deficit | (62,533,065) | (51,964,332) |
| Accumulated other comprehensive loss | (327,944) | (712,614) |
| Total consolidated Intelligent Bio Solutions Inc. equity | 2,996,136 | 8,329,350 |
| Non-controlling interest | (182,312) | (146,159) |
| Total shareholders’ equity | 2,813,824 | 8,183,191 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $8,249,786 | $13,778,863 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.